Wave Life Sciences Ltd.
For the period ended Mar 31, 2026. Filed Apr 28, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 28, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the three months ended March 31, 2026, certain of our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors entered into contracts, instructions or written plans (each, a “Rule 10b5-1 Trading Plan” and collectively, the “Rule 10b5-1 Trading Plans”) for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. We describe the material terms of these Rule 10b5-1 Trading Plans below.
On March 6, 2026, Mark Corrigan, M.D., a member of our board of directors, adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 31,500 of our ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Dr. Corrigan’s Rule 10b5-1 Trading Plan is active until September 12, 2026, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.
On March 6, 2026, Adrian Rawcliffe, a member of our board of directors, adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 33,700 of our ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Mr. Rawcliffe’s Rule 10b5-1 Trading Plan is active until February 26, 2027, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.
On March 11, 2026, Gregory Verdine, Ph.D., a member of our board of directors, adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 30,000 of our ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Dr. Verdine’s Rule 10b5-1 Trading Plan is active until December 31, 2026, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.
On March 6, 2026, Heidi Wagner, a member of our board of directors, adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 28,000 of our ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Ms. Wagner’s Rule 10b5-1 Trading Plan is active until March 5, 2027, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.
Except as disclosed above, none of our directors or executive officers adopted, modified orterminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as such term is defined in Item 408(a) of Regulation S-K, during the fiscal quarter ended March 31, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.